Fabio Ius MD
Hannover Medical School, Hannover, Germany
CONCURRENT SESSION 40: Lung AMR: HLA and Beyond -- Human Intravenous Immunoglobulins With Rituximab vs. Therapeutic Plasma Exchange With Rituximab for Pre-Emptive Treatment of Early Donors Specific Antibodies After Lung Transplantation: Preliminary Result
Antibody Mediated Rejection 2014: HLA and Beyond
CONCURRENT SESSION 50: Recipient Factors and Outcome After Lung Transplantation - Are We Getting It Right? -- IgM Enriched Human Immunoglobulins and Rituximab Nullify the Mortality Risk Associated with Early Donor Specific Antibodies After Lung Transplant
SESSION 30: Novel Mechanisms in Chronic Lung Allograft Dysfunction
ORAL SESSION 10 - Mechanisms of Allograft Injury after Lung Transplantation
ORAL SESSION 22 - Trials and Treatments in Lung Transplantation
RESEARCH SESSION 11: Chronic Lung Allograft Dysfunction: Overcoming the Hurdle?
RESEARCH SESSION 29: Pediatric Lung Transplantation: Are We Moving Forward?
ORAL: Novel Predictors and Risk Factors for Chronic Lung Allograft Dysfunction
ORAL: Latest Insights into Antibody Mediated Lung Allograft Rejection
ORAL: Mechanistic Processes of Primary Graft Dysfunction and Outcomes of ECMO Post Lung Transplantation
ORAL: Optimizing Outcomes Post Lung Transplantation
© 2020 Digitell, Inc. All Rights Reserved